한글목차

세계 체외수정(IVF) 시장 규모는 2024년 9억 4,900만 달러에서 2029년 16억 5,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 11.7%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.

보조생식술 기술의 개선으로 인한 치료 효과의 향상, 헬스케어의 불임 치료 서비스 적용 범위 확대, 건강 생식 문제를 전문적으로 다루는 고도의 자격을 갖춘 전문가가 있는 전문 클리닉의 가용성 등 다양한 요인이 수요를 주도하고 있습니다. 억제요인으로는 높은 치료 비용으로 인해 많은 사람들과 부부에게 치료 비용이 부담스러울 수 있다는 점을 들 수 있습니다.

체외수정을 성공적으로 수행하기 위해 필수적인 장비의 유형과 그 개발에 대해 알아보자. 한마디로 체외수정은 주로 배아 배양 인큐베이터, 미세 수정에 사용되는 마이크로 매니퓰레이터, 배아 및 배우자 보존에 사용되는 냉동 보존 시스템과 같은 특수 도구에 의존하고 있습니다. 첨단 영상 기술은 생존 가능한 배아를 선별하는 데 있어 타임랩스 촬영을 가능하게 하고, 유전자 스크리닝 분야의 차세대 시퀀싱 도구는 배아의 품질 평가를 향상시킵니다. 의료 기술의 발전과 함께 체외수정 장비도 혁신이 이루어지고 있습니다. 이러한 혁신적 연구는 제도화되고 더 큰 산업 이니셔티브에 의해 뒷받침되고 있으며, 성공률과 전반적인 환자 결과를 지속적으로 향상시키고 있습니다. 안전성과 유효성을 보장하는 규제 기준부터 불임 치료의 적용 범위를 확대하는 의료 정책, 그리고 전 세계적으로 체외수정 기기를 사용할 수 있도록 하는 최고의 역할에 이르기까지, 이러한 요소들이 결합되어 불임 치료를 필요로 하는 더 많은 사람들을 위한 최신 혁신 생식 솔루션이 개발되고 있습니다. 불임 치료를 필요로 하는 더 많은 사람들을 위해 최신 혁신 생식 솔루션이 개발되고 있습니다.

이 보고서는 세계 체외수정(IVF) 시장을 조사했으며, 제품별/기기별/시술별/주기별/최종사용자별/지역별 동향, 시장 진출기업 프로파일 등을 정리했습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 밸류체인 분석
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 가격 분석
• Porter의 Five Forces 분석
• 특허 분석
• 무역 데이터 분석
• 2024-2025년 주요 컨퍼런스 및 이벤트
• 주요 이해관계자와 구입 기준
• 미충족 요구
• 생태계 분석
• 공급망 분석
• 기술 분석
• 사례 연구 분석
• 규제 상황
• 투자와 자금조달 시나리오
• 환급 시나리오
• 생성형 AI가 체외수정(IVF) 시장에 미치는 영향

제6장 체외수정(IVF) 시장(제품별)

• 서론
• 장비
• 시약 및 배지
• 액세서리

제7장 체외수정(IVF) 시장(사이클별)

• 서론
• 신규 비기증자
• 동결 비기증자
• 동결 기증자
• 신규 기증자

제8장 체외수정(IVF) 시장(시술별)

• 서론
• 기존 체외수정
• 세포질내 정자 주입에 의한 체외수정
• 저침습 체외수정
• 기증자 난자를 사용한 체외수정
• 기타

제9장 체외수정(IVF) 시장(최종사용자별)

• 서론
• 불임 치료 클리닉 및 체외수정 센터
• 병원 및 외과센터
• 연구기관
• 크라이오뱅크

제10장 체외수정(IVF) 시장(지역별)

• 서론
• 아시아태평양
• 유럽
• 북미
• 라틴아메리카
• 중동 및 아프리카

제11장 경쟁 구도

• 개요
• 주요 시장 진출기업의 전략/비책
• 매출 분석
• 시장 점유율 분석
• 기업 평가 매트릭스 : 주요 시장 진출기업, 2023년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
• 기업 가치 평가와 재무 지표
• 브랜드/제품 비교
• 경쟁 시나리오

제12장 기업 개요

• 주요 시장 진출기업
  • COOPERSURGICAL, INC.
  • VITROLIFE
  • COOK MEDICAL INC.
  • HAMILTON THORNE
  • THERMO FISHER SCIENTIFIC INC.
  • FUJIFILM IRVINE SCIENTIFIC
  • KITAZATO CORPORATION
  • ESCO MICRO PTE. LTD.
  • FERTIPRO NV
  • GENEA BIOMEDX
  • NIKON CORPORATION
  • OLYMPUS
  • CORNING INCORPORATED
  • CARL ZEISS MICROSCOPY GMBH
  • EPPENDORF
  • MEIJI TECHNO
  • LEICA MICROSYSTEMS
  • GE HEALTHCARE
• 기타 기업
  • BIOIMAGER
  • ALLWIN MEDICAL DEVICES
  • SHANGHAI UNICORN MEDICAL TECHNOLOGY
  • GYNEMED
  • INVITROCARE
  • IVFTECH
  • LABIVF
  • MONASH BIOTECH
  • HUNTER SCIENTIFIC
  • CALIBRE SCIENTIFIC
  • SHIVANI SCIENTIFIC INDUSTRIES(P) LTD.
  • MINITUBE HUMAN ART

제13장 부록

영문목차

The global in vitro fertilization market is projected to reach USD 1,650 million by 2029 from USD 949 million in 2024, growing at a CAGR of 11.7% during the forecast period. The projected market growth for in vitro fertilization is supported by the convergence of benefits. In Vitro Fertilization convergence of advantages supports the projected market growth of this industry. In vitro fertilization: A host of factors drives the demand, from improvements in assisted reproductive technologies improving treatment efficacy to expanded fertility service coverage by healthcare and availability of specialized clinics with highly qualified professionals specialized in health reproduction issues. The restraints are the high cost of the procedure that may put treatment beyond the reach of too many people or even couples..

"IVF EquipmentsS to register largest market share in 2022-2029."

The kinds of equipment that are essential to dispensation of IVF treatment and their development for its success. In a nutshell, IVF mainly relies upon specialized tools such as embryo culture incubators, micromanipulators used for ICSI, and the cryopreservation systems used in the storage of embryos and gametes. Advanced imaging technologies allow for time-lapse imaging in the selection of viable embryos, and next-generation sequencing tools in the field of genetic screening improve embryo quality assessment. Together with advances in medical technology, IVF equipment is undergoing innovation. Such innovative research is institutionalized and underpinned by larger industrial initiatives that continue to drive success rates and overall patient outcomes. From the regulatory standards ensuring safety and effectiveness, to the healthcare policies increasing coverage for infertility treatments, and the highest role in making IVF equipment available worldwide, these combine to drive technological evolution and put the newest innovations in reproductive solutions before more and more people in need of fertility assistance..

"Fertility Clinics & IVF Centres segment held the largest share of in vitro fertilization market in 2023, by End-user."

Based on the end-user, the in vitro fertilization market is segmented into fertility clinics & IVF centres, hospitals, surgical centers, and cryobanks. In the year 2023, the global in vitro fertilization market was dominated by hospitals and clinics. The growth of the hospital & clinic segment is getting accelerated.

By speeding up the problems of infertility, increasing IVF procedures for early detection of possible complications, and introducing continuous advanced technologies.

"Fresh non donor to register highest growth rate in the market during the forecast period."

By Cycle Fresh Donor, Frozen Donor, Frozen Non Donor, Fresh Non Donor. Fresh non-donor is likely to grow at the fastest rate in the period from 2024-2029. Geographically On the basis of several leading and niche products, the market has been expounded,, and. with All the Reason the Market Seeing So Many Inexperienced Joiners without a Donor Vehicle. Whereas before, high entry barriers were powered by technologies and broad availability, which let people get involved in these app-based schemes without experience or donor vehicles..

"Asia Pacific to register highest growth rate in the market during the forecast period."

The highest CAGR is likely to be registered by the APAC region throughout the forecast period from 2024-2029. Asia Pacific is made up of India, China, Japan, South Korea, Australia, and RoAPAC. The Asia-Pacific region has reflected the highest upsurge in the market growth rate for in vitro fertilization.

The majority of the share of in vitro fertilization (IVF) markets in the Asia-Pacific are top for a number of indispensable reasons With a number of important considerations countries in the Asia Pacific region now own the highest share of the in vitro fertilization market. First and foremost, IVF service needs have increased due to rising rates of infertility, commonality in delayed childbearing, and changes in lifestyle. Better infrastructural facilities in healthcare, rising disposable incomes, and increasing awareness about fertility treatments are making more countries across this region accept and procure IVF. Added to these is the development of reproductive technologies and government programs encouraging fertility treatments, which support the growth of the Asia Pacific industry.

A number of drivers were responsible for the upswing, including:

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3- 28%
• By Designation: C-level-- 10%, Director-level-14%, and Others-76%
• By Region: North America-40%, Europe-30%, Asia Pacific-22%, Rest of the world-8%

Prominent players in this market are Cooper companies inc.(US), Cook Medical Inc.(US),Vitrolife(Europe), Fujifilm Irvine scientific(Japan),Hamilton thorne ltd.(US), Thermo fisher scientific(US), Nikon corporation(Japan), Olympus(Japan), Kitazato corporation(Japan), Corning incorporated(US), Zeiss group(Europe), Fertipro nv(Europe), Eppendorf(Europe) among others.

Research Coverage

The segmentation is based on products, cycle, procedure, end user, and region. The report analyzes the factors that have been affecting and will affect the growth of the market, including drivers, restraints, opportunities, and challenges. The report details opportunities and challenges in the in vitro fertilization market for stakeholders. Further details on competitive landscapes for market leaders are also provided. This report evaluates micro-markets with respect to the growth trends, prospects, and contributions towards the global in vitro fertilization market. The report expects the revenues of the segments of the market to increase with a view of five major regions.

Key Benefits of Buying the Report:

• The report intends to help new entrants, it addresses the availability of comprehensive data to help new entrants, top players of the in vitro fertilization market, and small enterprises understand investment viability. It shall aid processes of robust risk assessment and which investment decisions. It offers precise segmentation of markets, like that based on end-users and regional dimensions, hence giving targeted segments tailored insights. It also evaluates the highest trends, challenges, growth drivers, and opportunities for the same, thereby empowering strategic decision-making with insightful judgment.

The report provides the insights on the following pointers:

Analysis of the key drivers, restraints, opportunities, and challenges influencing the rise of the in vitro fertilization market: Advanced technology and ageing population of women; high cost of IVF procedures and ethical concerns; growing number of fertility clinics and increased treatment option.They have declined infertility treatment among women of high age.

Product Development/Innovation: Insights into pipeline technologies, research & development activities, and new product & service launches in the in vitro fertilization market.

Market Development: Detailed information about lucrative markets-the report analyses the in vitro fertilization market across varied regions.

Market Diversification: Detailed insight into new products, untapped geographies, recent developments, and investments in the in vitro fertilization market.

Competitive Assessment: Detailed assessment of market share, service offerings leading strategies of key players such as CooperSurgical Inc.(US), Vitrolife (Sweden), Cook Medical Inc.(US), Hamilton Thorne (US) and Thermo Fisher Scientific(US) among others.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH DESIGN
  • 2.2.1 SECONDARY RESEARCH
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY RESEARCH
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key industry insights
    • 2.2.2.3 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Company revenue estimation approach
    • 2.3.1.2 Customer-based market estimation
    • 2.3.1.3 Growth forecast approach
    • 2.3.1.4 CAGR projections
• 2.4 DATA TRIANGULATION
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 GROWTH RATE ASSUMPTIONS
• 2.8 RESEARCH LIMITATIONS
• 2.9 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 IN VITRO FERTILIZATION MARKET OVERVIEW
• 4.2 IN VITRO FERTILIZATION MARKET, BY REGION
• 4.3 ASIA PACIFIC IN VITRO FERTILIZATION MARKET, BY COUNTRY AND END USER, 2023
• 4.4 GEOGRAPHIC SNAPSHOT OF IN VITRO FERTILIZATION MARKET

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing median age of pregnancy
    • 5.2.1.2 Rising infertility rate
    • 5.2.1.3 Booming fertility industry
    • 5.2.1.4 Evolving technological landscape
    • 5.2.1.5 Favorable government initiatives
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of IVF procedures
    • 5.2.2.2 Social and ethical concerns in developing countries
    • 5.2.2.3 Elevated risk of complications
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging economies
    • 5.2.3.2 Availability of diverse range of fertility treatment options
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Reduced efficacy of infertility treatments for patients of advanced age
• 5.3 VALUE CHAIN ANALYSIS
  • 5.3.1 RESEARCH & DEVELOPMENT
  • 5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
  • 5.3.3 MARKETING & SALES, DISTRIBUTION, AND POST-SALES SERVICES
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.5.2 AVERAGE SELLING PRICE TREND OF TOP 3 ACCESSORIES, BY KEY PLAYER
• 5.6 PORTER'S FIVE FORCES ANALYSIS
  • 5.6.1 THREAT OF NEW ENTRANTS
  • 5.6.2 THREAT OF SUBSTITUTES
  • 5.6.3 BARGAINING POWER OF SUPPLIERS
  • 5.6.4 BARGAINING POWER OF BUYERS
  • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.7 PATENT ANALYSIS
• 5.8 TRADE DATA ANALYSIS
  • 5.8.1 IMPORT DATA
  • 5.8.2 EXPORT DATA
• 5.9 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 BUYING CRITERIA
• 5.11 UNMET NEEDS
• 5.12 ECOSYSTEM ANALYSIS
• 5.13 SUPPLY CHAIN ANALYSIS
  • 5.13.1 PROMINENT COMPANIES
  • 5.13.2 SMALL AND MEDIUM-SIZED ENTERPRISES
  • 5.13.3 END USERS
• 5.14 TECHNOLOGY ANALYSIS
  • 5.14.1 KEY TECHNOLOGIES
    • 5.14.1.1 Time-lapse technology
  • 5.14.2 COMPLEMENTARY TECHNOLOGIES
    • 5.14.2.1 Preimplantation genetic testing
  • 5.14.3 ADJACENT TECHNOLOGIES
    • 5.14.3.1 Sperm cryopreservation
    • 5.14.3.2 Oocyte cryopreservation
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 ENHANCED IVF RATES USING EMBRYOTOXICITY, PLATELET LEUKOCYTE AGGREGATES, AND NATURAL KILLER DIAGNOSIS
• 5.16 REGULATORY LANDSCAPE
  • 5.16.1 REGULATORY STANDARDS AND APPROVALS
    • 5.16.1.1 North America
      • 5.16.1.1.1 US
      • 5.16.1.1.2 Canada
    • 5.16.1.2 Europe
    • 5.16.1.3 Asia Pacific
      • 5.16.1.3.1 India
      • 5.16.1.3.2 Japan
  • 5.16.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.17 INVESTMENT AND FUNDING SCENARIO
• 5.18 REIMBURSEMENT SCENARIO
• 5.19 IMPACT OF GEN AI ON IN VITRO FERTILIZATION MARKET

6 IN VITRO FERTILIZATION MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 EQUIPMENT
  • 6.2.1 MICROSCOPES
    • 6.2.1.1 Need for assessing cell division and morphology during embryo development to drive market
  • 6.2.2 IMAGING SYSTEMS
    • 6.2.2.1 Need for real-time monitoring of oocytes and embryos to fuel market
  • 6.2.3 SPERM ANALYZER SYSTEMS
    • 6.2.3.1 Capability to identify fertility problems and determine appropriate interventions to fuel market
  • 6.2.4 OVUM ASPIRATION PUMPS
    • 6.2.4.1 Optimized retrieval of viable eggs and shortened procedure duration to aid growth
  • 6.2.5 MICROMANIPULATOR SYSTEMS
    • 6.2.5.1 Increased adoption in intracytoplasmic sperm injections and embryo biopsies to boost market
  • 6.2.6 INCUBATORS
    • 6.2.6.1 Time-lapse incubators
      • 6.2.6.1.1 Non-invasive techniques to propel market
    • 6.2.6.2 Other incubators
  • 6.2.7 GAS ANALYZERS
    • 6.2.7.1 Ability to replicate natural conditions of human reproductive system to drive market
  • 6.2.8 CRYOSYSTEMS
    • 6.2.8.1 Higher flexibility to use stored embryos, sperm, and eggs to support market growth
  • 6.2.9 LASER SYSTEMS
    • 6.2.9.1 Precise embryo manipulation and observation to augment growth
  • 6.2.10 SPERM SEPARATION SYSTEMS
    • 6.2.10.1 Need to maintain stable and optimal conditions in controlled environment to stimulate segment growth
  • 6.2.11 CABINETS
    • 6.2.11.1 Rising awareness about biological safety of IVF to boost market
  • 6.2.12 ANTI-VIBRATION TABLES
    • 6.2.12.1 Growing need for improved procedural accuracy to fuel market
  • 6.2.13 WITNESS SYSTEMS
    • 6.2.13.1 Rigorous safety and quality assurance standards to stimulate growth
  • 6.2.14 OTHER EQUIPMENT
• 6.3 REAGENTS & MEDIA
  • 6.3.1 EMBRYO CULTURE MEDIA
    • 6.3.1.1 Enhanced health and viability during embryo culture to aid growth
  • 6.3.2 CRYOPRESERVATION MEDIA
    • 6.3.2.1 Ability to protect cells from damage to drive market
  • 6.3.3 SPERM PROCESSING MEDIA
    • 6.3.3.1 Use in washing, capacitation, and sperm selection applications to boost segment
  • 6.3.4 OVUM PROCESSING MEDIA
    • 6.3.4.1 Ability to mimic natural conditions of female reproductive tract to propel market
• 6.4 ACCESSORIES
  • 6.4.1 GROWING INCLINATION TOWARD COMFORTABLE IVF PROCEDURE TO SUPPORT GROWTH

7 IN VITRO FERTILIZATION MARKET, BY TYPE OF CYCLE

• 7.1 INTRODUCTION
• 7.2 FRESH NON-DONORS
  • 7.2.1 RISING PREFERENCE FOR TREATMENT AMONG YOUNGER WOMEN TO AUGMENT GROWTH
• 7.3 FROZEN NON-DONORS
  • 7.3.1 IMPROVED EGG QUALITY AND FLEXIBLE SCHEDULING TO BOOST MARKET
• 7.4 FROZEN DONORS
  • 7.4.1 GROWING INCLINATION TOWARD READY-TO-USE HEALTHY EGGS TO FUEL MARKET
• 7.5 FRESH DONORS
  • 7.5.1 HIGHER CHANCE OF FERTILIZATION AND EMBRYO DEVELOPMENT TO PROPEL MARKET

8 IN VITRO FERTILIZATION MARKET, BY PROCEDURE

• 8.1 INTRODUCTION
• 8.2 CONVENTIONAL IVF
  • 8.2.1 PROVEN SUCCESS RATE IN ADDRESSING INFERTILITY ISSUES TO DRIVE MARKET
• 8.3 IVF WITH INTRACYTOPLASMIC SPERM INJECTIONS
  • 8.3.1 HIGHER SUCCESS RATES THAN CONVENTIONAL METHODS TO STIMULATE GROWTH
• 8.4 MINIMAL IVF
  • 8.4.1 RISING EMPHASIS ON MINIMIZED POTENTIAL SIDE EFFECTS TO SUPPORT MARKET
• 8.5 IVF WITH DONOR EGGS
  • 8.5.1 ABILITY TO ADDRESS PREMATURE OVARIAN FAILURE OR GENETIC DISORDERS TO AUGMENT GROWTH
• 8.6 OTHER PROCEDURES

9 IN VITRO FERTILIZATION MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 FERTILITY CLINICS & IVF CENTERS
  • 9.2.1 INCREASED AVAILABILITY AND ACCESSIBILITY TO FUEL MARKET
• 9.3 HOSPITALS & SURGICAL CENTERS
  • 9.3.1 NEED FOR ADVANCED LABORATORIES FOR GAMETE HANDLING AND ULTRASOUND MONITORING TO FUEL MARKET
• 9.4 RESEARCH INSTITUTES
  • 9.4.1 ONGOING RESEARCH FOR COST-EFFECTIVE AND ADVANCED TECHNIQUES TO BOOST MARKET
• 9.5 CRYOBANKS
  • 9.5.1 GROWING INCLINATION TOWARD FLEXIBLE TREATMENT TO AID MARKET GROWTH

10 IN VITRO FERTILIZATION MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 ASIA PACIFIC
  • 10.2.1 CHINA
    • 10.2.1.1 Increasing medical benefits for childbirth to drive market
  • 10.2.2 JAPAN
    • 10.2.2.1 Low fertility rates to support market growth
  • 10.2.3 INDIA
    • 10.2.3.1 Affordable treatment options to fuel market
  • 10.2.4 AUSTRALIA
    • 10.2.4.1 Declining fertility rate to propel market
  • 10.2.5 SOUTH KOREA
    • 10.2.5.1 Growing focus on reversing low population trend to stimulate growth
  • 10.2.6 REST OF ASIA PACIFIC
• 10.3 EUROPE
  • 10.3.1 GERMANY
    • 10.3.1.1 Robust healthcare infrastructure to support market growth
  • 10.3.2 UK
    • 10.3.2.1 Growing focus on high-quality care at licensed fertility clinics to propel market
  • 10.3.3 FRANCE
    • 10.3.3.1 Rising age of women at first birth to boost market
  • 10.3.4 ITALY
    • 10.3.4.1 Regulatory guidelines to govern market
  • 10.3.5 SPAIN
    • 10.3.5.1 Booming medical tourism to drive market
  • 10.3.6 REST OF EUROPE
• 10.4 NORTH AMERICA
  • 10.4.1 US
    • 10.4.1.1 Favorable infrastructure network to drive market
  • 10.4.2 CANADA
    • 10.4.2.1 Growing assistance from banks for fertility treatments to fuel market
• 10.5 LATIN AMERICA
  • 10.5.1 BRAZIL
    • 10.5.1.1 Decrease in percentage of women under 30 years of age to stimulate growth
  • 10.5.2 MEXICO
    • 10.5.2.1 Growing network of state-of-the-art facilities to aid market growth
  • 10.5.3 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 GCC COUNTRIES
    • 10.6.1.1 Improving health infrastructure and better awareness about fertility treatments to propel market
  • 10.6.2 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IN VITRO FERTILIZATION MARKET
• 11.3 REVENUE ANALYSIS
• 11.4 MARKET SHARE ANALYSIS
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Product footprint
    • 11.5.5.3 End-user footprint
    • 11.5.5.4 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.7.1 FINANCIAL METRICS
  • 11.7.2 COMPANY VALUATION
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 11.9.2 DEALS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 COOPERSURGICAL, INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 VITROLIFE
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 COOK MEDICAL INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches and approvals
      • 12.1.3.3.2 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 HAMILTON THORNE
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Right to win
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 THERMO FISHER SCIENTIFIC INC.
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 MnM view
      • 12.1.5.3.1 Right to win
      • 12.1.5.3.2 Strategic choices
      • 12.1.5.3.3 Weaknesses and competitive threats
  • 12.1.6 FUJIFILM IRVINE SCIENTIFIC
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches and approvals
      • 12.1.6.3.2 Other developments
  • 12.1.7 KITAZATO CORPORATION
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 ESCO MICRO PTE. LTD.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Deals
  • 12.1.9 FERTIPRO NV
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 GENEA BIOMEDX
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Deals
  • 12.1.11 NIKON CORPORATION
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
  • 12.1.12 OLYMPUS
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 CORNING INCORPORATED
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
  • 12.1.14 CARL ZEISS MICROSCOPY GMBH
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
  • 12.1.15 EPPENDORF
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Deals
  • 12.1.16 MEIJI TECHNO
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products offered
  • 12.1.17 LEICA MICROSYSTEMS
    • 12.1.17.1 Business overview
    • 12.1.17.2 Products offered
  • 12.1.18 GE HEALTHCARE
    • 12.1.18.1 Business overview
    • 12.1.18.2 Products offered
    • 12.1.18.3 Recent developments
      • 12.1.18.3.1 Product launches and approvals
      • 12.1.18.3.2 Deals
• 12.2 OTHER COMPANIES
  • 12.2.1 BIOIMAGER
  • 12.2.2 ALLWIN MEDICAL DEVICES
  • 12.2.3 SHANGHAI UNICORN MEDICAL TECHNOLOGY
  • 12.2.4 GYNEMED
  • 12.2.5 INVITROCARE
  • 12.2.6 IVFTECH
  • 12.2.7 LABIVF
  • 12.2.8 MONASH BIOTECH
  • 12.2.9 HUNTER SCIENTIFIC
  • 12.2.10 CALIBRE SCIENTIFIC
  • 12.2.11 SHIVANI SCIENTIFIC INDUSTRIES (P) LTD.
  • 12.2.12 MINITUBE HUMAN ART

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS